About
Developing a preservative-free, stabilised low-dose atropine formulation (SYD-101) for myopia progression in children — the drug arm of the myopia-management wave.
HQ: US
Funding
VC-backed (Series B closed 2022)
—Company profile
Low-dose atropine (SYD-101) — a pharmaceutical approach to slowing childhood myopia.
Developing a preservative-free, stabilised low-dose atropine formulation (SYD-101) for myopia progression in children — the drug arm of the myopia-management wave.
HQ: US